{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:29:33Z","timestamp":1793694573829,"version":"4.5.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-1-0139"],"award-info":[{"award-number":["W81XWH-12-1-0139"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P30 CA168524"],"award-info":[{"award-number":["P30 CA168524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13058-019-1140-1","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T11:00:10Z","timestamp":1557140410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Olivia K.","family":"Provance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6170-1463","authenticated-orcid":false,"given":"Joan","family":"Lewis-Wambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"13","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","volume":"97","author":"KW Hance","year":"2005","unstructured":"Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.7150\/jca.23969","volume":"9","author":"NT Ueno","year":"2018","unstructured":"Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, et al. International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018;9(8):1437\u201347.","journal-title":"J Cancer"},{"issue":"20","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2004.04.068","volume":"22","author":"JA Low","year":"2004","unstructured":"Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22(20):4067\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5\u201323.","journal-title":"Mol Oncol"},{"issue":"17","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-12-2549","volume":"19","author":"SJ Van Laere","year":"2013","unstructured":"Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013;19(17):4685\u201396.","journal-title":"Clin Cancer Res"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"4754827","DOI":"10.1155\/2017\/4754827","volume":"2017","author":"RJ Morrow","year":"2017","unstructured":"Morrow RJ, Etemadi N, Yeo B, Ernst M. Challenging a misnomer? The role of inflammatory pathways in inflammatory breast cancer. Mediat Inflamm. 2017;2017:4754827.","journal-title":"Mediat Inflamm"},{"issue":"6","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/bcr3579","volume":"15","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013;15(6):R112.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","volume":"18","author":"Bora Lim","year":"2018","unstructured":"Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer.\u00a02018;18:485-89.","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2015.02.018","volume":"361","author":"H Luo","year":"2015","unstructured":"Luo H, Tu G, Liu Z, Liu M. Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett. 2015;361(2):155\u201363.","journal-title":"Cancer Lett"},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.biocel.2013.11.015","volume":"46","author":"MM Mohamed","year":"2014","unstructured":"Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol. 2014;46:138\u201347.","journal-title":"Int J Biochem Cell Biol"},{"key":"1140_CR11","doi-asserted-by":"publisher","first-page":"39190","DOI":"10.1038\/srep39190","volume":"6","author":"SG Allen","year":"2016","unstructured":"Allen SG, Chen YC, Madden JM, Fournier CL, Altemus MA, Hiziroglu AB, et al. Macrophages enhance migration in inflammatory breast cancer cells via RhoC GTPase signaling. Sci Rep. 2016;6:39190.","journal-title":"Sci Rep"},{"issue":"5","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/sj.bjc.6600807","volume":"88","author":"CG Colpaert","year":"2003","unstructured":"Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003;88(5):718\u201325.","journal-title":"Br J Cancer"},{"issue":"5","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.breast.2014.06.008","volume":"23","author":"F Bertucci","year":"2014","unstructured":"Bertucci F, Finetti P, Vermeulen P, Van Dam P, Dirix L, Birnbaum D, et al. Genomic profiling of inflammatory breast cancer: a review. Breast. 2014;23(5):538\u201345.","journal-title":"Breast."},{"issue":"1","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13058-016-0683-7","volume":"18","author":"J Ogony","year":"2016","unstructured":"Ogony J, Choi HJ, Lui A, Cristofanilli M, Lewis-Wambi J. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast Cancer Res. 2016;18(1):25.","journal-title":"Breast Cancer Res"},{"key":"1140_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha\/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307\u201336.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"1140_CR16","doi-asserted-by":"publisher","first-page":"R191","DOI":"10.1186\/gb-2007-8-9-r191","volume":"8","author":"M Buess","year":"2007","unstructured":"Buess M, Nuyten DS, Hastie T, Nielsen T, Pesich R, Brown PO. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol. 2007;8(9):R191.","journal-title":"Genome Biol"},{"issue":"18","key":"1140_CR17","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","volume":"292","author":"G Schreiber","year":"2017","unstructured":"Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017;292(18):7285\u201394.","journal-title":"J Biol Chem"},{"issue":"9","key":"1140_CR18","first-page":"41","volume":"24","author":"R Bordens","year":"1997","unstructured":"Bordens R, Grossberg SE, Trotta PP, Nagabbushan TL. Molecular and biologic charaterization of recombinant interferon-a2b. Semin Oncol. 1997;24(9):41\u201351.","journal-title":"Semin Oncol"},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cytogfr.2016.02.010","volume":"29","author":"K Blaszczyk","year":"2016","unstructured":"Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HA. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71\u201381.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1140_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","volume":"67","author":"GR Stark","year":"1998","unstructured":"Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227\u201364.","journal-title":"Annu Rev Biochem"},{"issue":"20","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/emboj.2013.203","volume":"32","author":"H Cheon","year":"2013","unstructured":"Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013;32(20):2751\u201363.","journal-title":"EMBO J"},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"1140_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ni1087","volume":"5","author":"M Yoneyama","year":"2004","unstructured":"Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730\u20137.","journal-title":"Nat Immunol"},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.","journal-title":"Front Immunol"},{"issue":"4","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cytogfr.2009.07.005","volume":"20","author":"P Genin","year":"2009","unstructured":"Genin P, Vaccaro A, Civas A. The role of differential expression of human interferon--a genes in antiviral immunity. Cytokine Growth Factor Rev. 2009;20(4):283\u201395.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7689","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature25432","volume":"553","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467\u201372.","journal-title":"Nature."},{"issue":"2","key":"1140_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.immuni.2015.01.012","volume":"42","author":"A Hartlova","year":"2015","unstructured":"Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity. 2015;42(2):332\u201343.","journal-title":"Immunity."},{"issue":"1","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-010-1026-5","volume":"128","author":"M Smid","year":"2011","unstructured":"Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, Wang Y, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011;128(1):23\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2007.05.019","volume":"129","author":"D Panne","year":"2007","unstructured":"Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell. 2007;129(6):1111\u201323.","journal-title":"Cell."},{"issue":"10","key":"1140_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.celrep.2017.02.037","volume":"18","author":"AS Qadir","year":"2017","unstructured":"Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, et al. CD95\/Fas increases stemness in cancer cells by inducing a STAT1-dependent type I interferon response. Cell Rep. 2017;18(10):2373\u201386.","journal-title":"Cell Rep"},{"issue":"41","key":"1140_CR32","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"R Medrano","year":"2017","unstructured":"Medrano R, Hunger A, Mendonca S, Barbuto J, Strauss B. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249\u201384.","journal-title":"Oncotarget."},{"issue":"11","key":"1140_CR33","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","volume":"18","author":"NN Khodarev","year":"2012","unstructured":"Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon\/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012;18(11):3015\u201321.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"1140_CR34","doi-asserted-by":"publisher","first-page":"10443","DOI":"10.1073\/pnas.1513341112","volume":"112","author":"PS Sung","year":"2015","unstructured":"Sung PS, Cheon H, Cho CH, Hong SH, Park DY, Seo HI, et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc Natl Acad Sci U S A. 2015;112(33):10443\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1140_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/jir.2011.0028","volume":"31","author":"LM Pfeffer","year":"2011","unstructured":"Pfeffer LM. The role of nuclear factor kappaB in the interferon response. J Interf Cytokine Res. 2011;31(7):553\u20139.","journal-title":"J Interf Cytokine Res"},{"issue":"2","key":"1140_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2141.2000.02017.x","volume":"109","author":"C Wickenhauser","year":"2000","unstructured":"Wickenhauser C, Schmitz B, Selbach B, Brockbals C, Manske O, Thiele J. Interferon alpha2b directly induces fibroblast proliferation and transforming growth factor beta secretion of macrophages. Br J Haematol. 2000;109(2):296\u2013304.","journal-title":"Br J Haematol"},{"issue":"2","key":"1140_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.seminoncol.2014.02.002","volume":"41","author":"H Cheon","year":"2014","unstructured":"Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. 2014;41(2):156\u201373.","journal-title":"Semin Oncol"},{"issue":"47","key":"1140_CR38","doi-asserted-by":"publisher","first-page":"18490","DOI":"10.1073\/pnas.0809242105","volume":"105","author":"RR Weichselbaum","year":"2008","unstructured":"Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008;105(47):18490\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1140_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2017.04.005","volume":"399","author":"AJ Lui","year":"2017","unstructured":"Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, et al. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK\/STAT-mediated induction of p21. Cancer Lett. 2017;399:29\u201343.","journal-title":"Cancer Lett"},{"issue":"1","key":"1140_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2015.07.034","volume":"368","author":"Fang Yu","year":"2015","unstructured":"Yu F, Xie D, Ng SS, Lum CT, Cai MY, Cheung WK, et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 2015;368(1):135\u201343.","journal-title":"Cancer Letters"},{"issue":"2","key":"1140_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-010-0377-4","volume":"103","author":"F Yu","year":"2011","unstructured":"Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, et al. Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neuro-Oncol. 2011;103(2):187\u201395.","journal-title":"J Neuro-Oncol"},{"issue":"19","key":"1140_CR42","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1158\/1078-0432.CCR-07-4761","volume":"14","author":"H Hatano","year":"2008","unstructured":"Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 2008;14(19):6097\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1140_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/cbr.2016.2046","volume":"31","author":"F Ahmed","year":"2016","unstructured":"Ahmed F, Mahmood N, Shahid S, Hussain Z, Ahmed I, Jalal A, et al. Mutations in human interferon alpha2b gene and potential as risk factor associated with female breast cancer. Cancer Biother Radiopharm. 2016;31(6):199\u2013208.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"1140_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2014.07.258","volume":"71","author":"OY Leplina","year":"2015","unstructured":"Leplina OY, Tyrinova TV, Tikhonova MA, Ostanin AA, Chernykh ER. Interferon alpha induces generation of semi-mature dendritic cells with high pro-inflammatory and cytotoxic potential. Cytokine. 2015;71(1):1\u20137.","journal-title":"Cytokine."},{"key":"1140_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Coppe","year":"2010","unstructured":"Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99\u2013118.","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"1140_CR46","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/0008-5472.CAN-05-0784","volume":"65","author":"B Huang","year":"2005","unstructured":"Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65(12):5009\u201314.","journal-title":"Cancer Res"},{"issue":"12","key":"1140_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37(12):855\u201365.","journal-title":"Trends Immunol"},{"issue":"6","key":"1140_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/PPO.0000000000000007","volume":"19","author":"K Palucka","year":"2013","unstructured":"Palucka K, Coussens LM, O'Shaughnessy J. Dendritic cells, inflammation, and breast cancer. Cancer J. 2013;19(6):511\u20136.","journal-title":"Cancer J"},{"issue":"22","key":"1140_CR49","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1158\/1078-0432.CCR-04-0684","volume":"10","author":"I Treilleux","year":"2004","unstructured":"Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466\u201374.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1140_CR50","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","volume":"72","author":"V Sisirak","year":"2012","unstructured":"Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72(20):5188\u201397.","journal-title":"Cancer Res"},{"key":"1140_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","volume":"17","author":"S Sousa","year":"2015","unstructured":"Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Monkkonen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.","journal-title":"Breast Cancer Res"},{"key":"1140_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-0-387-69116-9_5","volume":"604","author":"C Porta","year":"2007","unstructured":"Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, Sica A. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol. 2007;604:67\u201386.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1140_CR53","doi-asserted-by":"publisher","first-page":"e58913","DOI":"10.1371\/journal.pone.0058913","volume":"8","author":"Peng-Yuan Zhuang","year":"2013","unstructured":"Zhuang PY, Shen J, Zhu XD, Tang ZY, Qin LX, Sun HC. Direct transformation of lung microenvironment by interferon-\u03b1 treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One. 2013;8(3):e58913.","journal-title":"PLoS ONE"},{"key":"1140_CR54","doi-asserted-by":"publisher","first-page":"13050","DOI":"10.1038\/ncomms13050","volume":"7","author":"R Allaoui","year":"2016","unstructured":"Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z, et al. Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun. 2016;7:13050.","journal-title":"Nat Commun"},{"issue":"6","key":"1140_CR55","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/1541-7786.MCR-11-0604","volume":"10","author":"DA Stewart","year":"2012","unstructured":"Stewart DA, Yang Y, Makowski L, Troester MA. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol Cancer Res. 2012;10(6):727\u201338.","journal-title":"Mol Cancer Res"},{"key":"1140_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-015-1117-0","volume":"15","author":"AN Hosein","year":"2015","unstructured":"Hosein AN, Livingstone J, Buchanan M, Reid JF, Hallett M, Basik M. A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. BMC Cancer. 2015;15:130.","journal-title":"BMC Cancer"},{"issue":"3","key":"1140_CR57","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/08916930903510963","volume":"43","author":"S Indraccolo","year":"2010","unstructured":"Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity. 2010;43(3):244\u20137.","journal-title":"Autoimmunity."},{"key":"1140_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jtbi.2018.05.003","volume":"452","author":"KA Norton","year":"2018","unstructured":"Norton KA, Jin K, Popel AS. Modeling triple-negative breast cancer heterogeneity: effects of stromal macrophages, fibroblasts and tumor vasculature. J Theor Biol. 2018;452:56\u201368.","journal-title":"J Theor Biol"},{"key":"1140_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","volume":"4","author":"DG Stover","year":"2018","unstructured":"Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, et al. Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018;4:10.","journal-title":"NPJ Breast Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1140-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:13:44Z","timestamp":1589534024000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1140-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"6 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"59"}}